

**Fresenius Kabi AG - Strategic SWOT Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, and Recent Trends**

Company Report | 2024-08-23 | 84 pages | Quintel Research

**AVAILABLE LICENSES:**

- Single User Price \$150.00
- Multi User Price \$175.00
- Enterprise User Price \$195.00

**Report description:**

Report Summary

Fresenius Kabi AG - Strategic SWOT Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, and Recent Trends Report is a comprehensive and easily accessible overview of Fresenius Kabi AG's business operations. It provides a detailed analysis of the company's strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.

The report begins with in-depth information about Fresenius Kabi AG including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.

Next, the report assesses Fresenius Kabi AG's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. By integrating these strategic analyses, the report offers a comprehensive understanding of Fresenius Kabi AG's overall strategic standing and supports informed decision-making and strategic planning.

Finally, the report includes recent news and deal activities undertaken by Fresenius Kabi AG enhancing awareness of the company's business trends, growth perspectives, and more.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## Key Highlights

Fresenius Kabi AG is a leading global healthcare company, specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. The company specializes in products for the therapy and care of critically and chronically ill patients. The portfolio includes biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs (generic IV drugs), and IV fluids. It have operations in over 100 countries and a workforce of approximately 40,000. With its Vision 2026, Fresenius Kabi has developed a strategic plan to transform the company for the next decade and to better capture new growth opportunities. Fresenius Kabi's corporate philosophy "caring for life" expresses the company's commitment to improving the quality of life of its patients. The quality and safety of its products and services is thus of paramount importance to Fresenius Kabi. The company have main research sites are in Europe, the United States, and India. The company have product-related development activities are also carried out in China.

## Fresenius Kabi AG in the News:-

- 05-Aug-2024 - Fresenius Kabi Receives 2024 Trailblazer Award From Premier Inc. For Supply Chain Innovation
- 31-Jul-2024 - Fresenius With Excellent Performance in Q2; Major Progress on Deleveraging on the Back of Strong Cash Flow: Entering Target Ratio Corridor; Outlook Confirmed and Optimistic About Second Half
- 26-Jul-2024 - Fresenius Kabi and Formycon Receive Positive CHMP Opinion for FYB202, an Ustekinumab Biosimilar Candidate
- 11-Jul-2024 - Fresenius Announces EMA Validation of Marketing Authorization Application for Denosumab Biosimilar Candidates
- 05-Jul-2024 - Ideas for a Better Tomorrow

## Scope

- Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
- Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
- Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
- Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.

## Reasons to Buy

- Comprehensive Understanding of the Fresenius Kabi AG's internal and external factors through SWOT analysis and Corporate Strategy.
- Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
- Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
- Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
- Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.

Additionally, available deep-dive analysis on the company Fresenius Kabi AG:

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Fresenius Kabi AG PESTLE Analysis
- Fresenius Kabi AG Value Chain Analysis
- Fresenius Kabi AG Porter's Five Forces Analysis
- Fresenius Kabi AG VRIO Analysis
- Fresenius Kabi AG BCG Analysis
- Fresenius Kabi AG Segmentation, Targeting and Positioning (STP) Analysis
- Fresenius Kabi AG Ansoff Matrix Analysis

## **Table of Contents:**

Table of Contents	
Table of Contents	2
Tables	6
Charts	7
Fresenius Kabi AG - Key Company Facts	8
Fresenius Kabi AG - Company Description	9
Fresenius Kabi AG - Top Executives	10
Fresenius Kabi AG - Top Executives Biographies	11
Fresenius Kabi AG - Head Office & Locations	13
Head Office - Country	13
Key Subsidiaries	14
Fresenius Kabi AG - Products and Services	16
Products	16
Fresenius Kabi AG - Historic Events	17
Fresenius Kabi AG - Company's Management Discussion	19
Fresenius Kabi AG - Company's Mission and Vision	22
Mission	22
Vision	22
Fresenius Kabi AG - Corporate Strategy	23
Fresenius Kabi AG - Business Description	29
Biopharma	30
Pharma	31
Medical Nutrition	32
MedTech	33
Fresenius Kabi AG - ESG Spotlight	35
Environment	35
Social	36
Corporate Governance	36
Fresenius Kabi AG - SWOT Analysis	37
Overview	37
Strengths	39
Weaknesses	42
Opportunities	44
Threats	47
Competing Players	49
Snapshot of Competing Players	50
Baxter International Inc.	50

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Key Company Facts	50
Company Description	50
Becton, Dickinson and Company	52
Key Company Facts	52
Company Description	52
Roche Holding AG	54
Key Company Facts	54
Company Description	54
Johnson & Johnson	56
Key Company Facts	56
Company Description	56
Pfizer Inc.	58
Key Company Facts	58
Company Description	58
Fresenius Kabi AG - Business Signals	60
Signal Sentiments Analytics	60
Signal Segments Analytics	61
Signal Segments by Sentiments Analytics	62
Signals by Sentiments Analytics	65
Fresenius Kabi AG - In the News	69
05-Aug-2024 - Fresenius Kabi Receives 2024 Trailblazer Award From Premier Inc. For Supply Chain Innovation	69
31-Jul-2024 - Fresenius With Excellent Performance in Q2; Major Progress on Deleveraging on the Back of Strong Cash Flow: Entering Target Ratio Corridor; Outlook Confirmed and Optimistic About Second Half	71
26-Jul-2024 - Fresenius Kabi and Formycon Receive Positive CHMP Opinion for FYB202, an Ustekinumab Biosimilar Candidate	73
11-Jul-2024 - Fresenius Announces EMA Validation of Marketing Authorization Application for Denosumab Biosimilar Candidates	75
05-Jul-2024 - Ideas for a Better Tomorrow	75
30-Nov-2023 - Fresenius Kabi and Formycon Announce FDA Submission Acceptance for Review for Ustekinumab Biosimilar Candidate	76
01-Nov-2023 - Fresenius Kabi Launches Tyenne*, the First Approved Tocilizumab Biosimilar in the European Union	77
31-Oct-2023 - Supporting Conscious Choices in Nutritional Care	77
25-Oct-2023 - Gastrointestinal Dysfunction Study Wins Inaugural ESICM Clinical Nutrition Award	77
29-Sep-2023 - Fresenius Kabi and Formycon Announce EMA Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate	77
19-Sep-2023 - Tyenne, Fresenius Kabi's Tocilizumab Biosimilar, Receives European Commission Approval	77
15-Sep-2023 - Fresenius Kabi Recognized as a Top Employer in 2023. Austria, China, Dominican Republic, Poland, Switzerland and the USA receive certificates	78
13-Sep-2023 - Jumpstart Clinical Nutrition Award Winner Announced at ESPEN Congress	78
17-Aug-2023 - Paving the Way for the Future of Blood Transfusions. Our novel blood bag system was subject of an award-winning clinical study	78
21-Jul-2023 - Fresenius Kabi's Tocilizumab Biosimilar Candidate MSB11456 Receives Positive CHMP Opinion	79
12-Jul-2023 - Fresenius Kabi's Denosumab Biosimilar Candidate FKS518 Shows Positive Clinical Trial Results	79
Fresenius Kabi AG - Key Deals	80
14-Dec-2023 - Fresenius Kabi and Mayo Clinic Enter into Multiyear Supply and Service Agreement for the Ivenix Infusion System	80
14-Sep-2023 - Virginia Oncology Associates Chooses the Ivenix Infusion System from Fresenius Kabi	80
24-Aug-2023 - Fresenius Kabi and Lupagen Enter Into Strategic Development and Supply Agreement to Bring Cell and Gene	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Therapies to the Bedside	80
07-Aug-2023 - Fresenius Kabi and Formycon Secure U.S. License Date for Proposed Ustekinumab Biosimilar	81
23-May-2023 - Fresenius Kabi Awarded Breakthrough Technology Agreement With Premier, Inc. For the Ivenix Infusion System	81
17-Apr-2023 - Vizient Innovative Technology Contract Awarded to Fresenius Kabi for the Ivenix Infusion System	81
02-Feb-2023 - Fresenius Kabi announces global license agreement with Formycon AG to commercialize proposed Ustekinumab biosimilar	81
10-Aug-2022 - Fresenius Kabi Establishes Partnership With Bio-Manguinhos/Fiocruz and Bionovis to Provide Access to Adalimumab Biosimilar in Brazil	81
01-Aug-2022 - Fresenius Kabi Completes Majority Stake Acquisition of mAbxience Holding S.L., Significantly Enhancing Presence in High-Growth Biopharmaceuticals Market	82
04-May-2022 - Fresenius Kabi completes acquisition of Ivenix, Inc., creating an industry-leading infusion therapies offering in the U.S.	82
Appendix	83
Definitions	83
SWOT Analysis	83
PESTLE Analysis	83
Value Chain Analysis	83
ESG Spotlight	83
Research Methodology	84
Disclaimer	85
Contact Us	85

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Fresenius Kabi AG - Strategic SWOT Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, and Recent Trends**

Company Report | 2024-08-23 | 84 pages | Quintel Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User Price	\$150.00
	Multi User Price	\$175.00
	Enterprise User Price	\$195.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-16"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Signature

An empty rectangular box with a thin black border, intended for a signature.